Obesity and liver disease

  • Ayman Koteish
  • Anna Mae Diehl
Treatment News

Conclusions

Obesity increases the risk for liver disease, including liver cancer. The mechanisms for this association are not well understood. At the very least, obesity might function as a comorbidity factor, accentuating processes (such as microsomal enzyme induction or pro-inflammatory cytokine production) that mediate liver damage caused by alcohol, hepatotoxic drugs, or certain viral infections. However, a growing body of evidence suggests that obesity-related insulin resistance plays a fundamental role in the initiation and progression of liver damage and liver cancer by altering the viability of liver cells. Efforts to delineate the molecular mechanisms that mediate insulin’s actions on cellular apoptosis and proliferation are increasing, and should help us design more effective therapies to prevent and treat obesity-related liver diseases.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Stevens J, Cai J, Pamuk ER, et al.: The effect of age on the association between body-mass index and mortality. N Engl J Med 1998, 338(1):1–7.PubMedCrossRefGoogle Scholar
  2. 2.
    Andres R, Muller DC, Sorkin JD: Long-term effects of change in body weight on all-cause mortality: a review. Ann Intern Med 1993, 119:737–743.PubMedGoogle Scholar
  3. 3.
    Manson JE, Wilett WC, Stampfer MJ, et al.: Body weight and mortality among women. N Engl J Med 1995, 333:677–685.PubMedCrossRefGoogle Scholar
  4. 4.
    Lindsted KD, Singh PN: Body mass and 26-year risk of mortality among women who never smoked: findings from the Adventist Mortality Study. Am J Epidemiol 1997, 146:1–11.PubMedGoogle Scholar
  5. 5.
    Naveau S, Giraud V, Borotto E, et al.: Excess weight risk factor for alcoholic liver disease. Hepatology 1997, 25:108–111.PubMedCrossRefGoogle Scholar
  6. 6.
    Poupon RY, Serfaty LD, Amorim M, et al.: Combination of steatosis and alcohol intake is the main determinant of fibrosis progression in patients with hepatitis C. Hepatology 1999, 30:406A.Google Scholar
  7. 7.
    Hodgson M, Van Thiel DH, Goodman-Klein B: Obesity and hepatotoxin risk factors for fatty liver disease. Br J Industr Med 1991, 48:690–695.Google Scholar
  8. 8.
    Ratziu V, Giral P, Charlotte F, et al.: Liver fibrosis in overweight patients. Gastroenterology 2000, 118:1117–1123.PubMedCrossRefGoogle Scholar
  9. 9.
    Heston W, Vlhakis G: Genetic obesity and neoplasia. J Natl Cancer Inst 1962, 29:197–209.PubMedGoogle Scholar
  10. 10.
    Galambos J: Natural history of alcoholic hepatitis III: histologic changes. Gastroenterology 1972, 56:515–522.Google Scholar
  11. 11.
    Morgan MY: The prognosis and outcome of alcoholic liver disease. Alcohol Alcohol 1994, 2(suppl):335–343.Google Scholar
  12. 12.
    Pequignot G, Tuyns AS, Berta JL: Ascitic cirrhosis in relationship to alcohol consumption. Int J Epidemiol 1978, 7:113–120.PubMedCrossRefGoogle Scholar
  13. 13.
    Lelbach WK: Epidemiology of alcoholic liver disease. Prog Liv Dis 1976, 5:494–513.Google Scholar
  14. 14.
    Iturriaga H, Bunout D, Hirsch S, Ugarte G: Overweight as a risk factor or a predictive sign of histological damage in alcoholics. Am J Clin Nutr 1988, 47:235–238.PubMedGoogle Scholar
  15. 15.
    Bellentani S, Tiribelli C, Saccoccio G, et al.: Prevalence of chronic liver disease in the general population of northern Italy: the Dyonisos study. Hepatology 1994, 20:1442–1449.PubMedGoogle Scholar
  16. 16.
    Braillon A, Capron JP, Herve MA, et al.: Liver in obesity. Gut 1985, 26:133–139.PubMedGoogle Scholar
  17. 17.
    Ludwig J, Viggiano RT, McGill DB: Nonalcoholic steatohepatitis. Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980, 55:342–348.Google Scholar
  18. 18.
    Clain DJ, Lefkowitch JH: Fatty liver disease in morbid obesity. Gastroenerol Clin North Am 1987, 16:239–252.Google Scholar
  19. 19.
    Fiore G, Fera G, Napoli N, et al.: Liver steatosis and chronic hepatitis C: a spurious association? Eur J Gastroenterol Hepatol. 1996, 8:125–129.PubMedCrossRefGoogle Scholar
  20. 20.
    Bizzaro N, Tremolada F, Casarin C, et al.: Serum alanine aminotransferase levels among volunteer blood donors: effect of sex, alcohol intake and obesity. Ital J Gastroenterol 1992, 24:237–241.PubMedGoogle Scholar
  21. 21.
    Anderson NA, Raafat A, Shwe KH, et al.: UK multicentre study on blood donors for surrogate markers of non-A, non-B hepatitis. Part I: Alanine transferase and anti-HBc testing. Transfus Med 1992, 2:301–310.PubMedGoogle Scholar
  22. 22.
    Lozano M, Cid J, Bedini JL, et al.: Study of serum alanine-aminotransferase levels in blood donors in Spain. Haematologica 1998, 83:237–239.PubMedGoogle Scholar
  23. 23.
    Goncales Junior FL, Stucchi RS, Papaiordanou PM, et al.: Elevated alanine aminotransferase (ALT) in blood donors: an assessment of the main associated conditions and its relationship to the development of hepatitis C. Rev Inst Med Trop Sao Paulo 1998, 40:219–224.PubMedGoogle Scholar
  24. 24.
    Camps J, Crisostomo S, Garcia-Granero M, et al.: Prediction of the response of chronic hepatitis C to interferon alfa: a statistical analysis of pretreatment variables. Gut 1993, 34:1714–1717.PubMedGoogle Scholar
  25. 25.
    Cotrim HP, Andrade ZA, Parana R, et al.: Nonalcoholic steatohepatitis: a toxic liver disease in industrial workers. Liver 1999, 19:299–304.PubMedCrossRefGoogle Scholar
  26. 26.
    de la Maza MP, Hirsch S, Petermann M, et al.: Changes in microsomal activity in alcoholism and obesity. Alcohol Clin Exp Res 2000, 24:605–610.PubMedGoogle Scholar
  27. 27.
    De Craemer D, Pauwels M, Van den Branden C: Alterations of peroxisomes in steatosis of the human liver: a quantitative study. Hepatology 1995, 22:744–752.PubMedCrossRefGoogle Scholar
  28. 28.
    Teli M, James OF, Burt AD, et al.: A natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995, 22:1714–1717.PubMedGoogle Scholar
  29. 29.
    el-Hassan AY, Ibrahim EM, al-Mulhim FA, et al.: Fatty infiltration of the liver: analysis of prevalence, radiological and clinical features and influence on patient management. Br J Radiol 1992, 65:774–778.PubMedGoogle Scholar
  30. 30.
    Nomura H, Kashiwagi S, Hayashi J, et al.: Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn J Med 1988, 27:142–149.PubMedGoogle Scholar
  31. 31.
    Caldwell SH, Oelsner DH, Iezzoni JC, et al.: Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999, 29:664–669.PubMedCrossRefGoogle Scholar
  32. 32.
    Matteoni C, Younossi ZM, McCullough A: Nonalcoholic fatty liver disease: a spectrum of clinical pathological severity. Gastroenterology 1999, 116:1413–1419.PubMedCrossRefGoogle Scholar
  33. 33.
    Bacon B, Faravash MJ, Janney CG, et al.: Nonalcoholic steatohepatitis: An expanded clinical entity. Gastroenterology. 1994, 107:1103–1106.PubMedGoogle Scholar
  34. 34.
    Powell EE, Searle J, Mortimer R: Steatohepatitis associated with limb lipodystrophy. Gastroenterology 1989, 97:1022–1024.PubMedGoogle Scholar
  35. 35.
    Angulo P, Deach JC, Batts KP, Lindor KD: Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999, 301356–62.PubMedCrossRefGoogle Scholar
  36. 36.
    Drenick EJ, Roslyn JJ: Cure of arthritis-dermatitis syndrome due to intestinal bypass by resection of nonfunction segment of blind loop. Dig Dis Sci 1990, 35:656–660.PubMedCrossRefGoogle Scholar
  37. 37.
    Jorizzo JL, Apisarnthanarax P, Subrt P, et al.: Bowel-bypass syndrome without bowel bypass. Bowel-associated dermatosis-arthritis syndrome. Arch Intern Med 1983, 143:457–461.PubMedCrossRefGoogle Scholar
  38. 38.
    Burke GW, Cirocco R, Hensely G, et al.: Liver transplantation for cirrhosis following jejunoileal bypass. Regional cytokine differences associated with pathological changes in the tranplanted liver. Transplantation 1992, 54:374–377.PubMedCrossRefGoogle Scholar
  39. 39.
    Cope K, Risby T, Diehl AM: Increased gastrointestinal ethanol production in obese mice: implications for fatty liver disease pathogenesis. Gastroenterology 2000, 119:1340–1347.PubMedCrossRefGoogle Scholar
  40. 40.
    Rosenbaum M, Leibel RL, Hirsch J: Obesity. N Engl J Med 1997, 337:396–407.PubMedCrossRefGoogle Scholar
  41. 41.
    Pi-Sunyer FX: Medical hazards of obesity. Ann Intern Med 1993, 119:655–660.PubMedGoogle Scholar
  42. 42.
    Powell EE, Cooksley GE, Hanson R, et al.: The natural history of nonalcoholic steatohepatitis: A follow-up study of 42 patients follow for up to 21 years. Hepatology 1990, 11:74–80.PubMedCrossRefGoogle Scholar
  43. 43.
    Schoen RE, Tangen CM, Kuller LH, et al.: Increased blood glucose, insulin, body size and incident colorectal cancer. J Natl Cancer Inst 1999, 91:1147–1154.PubMedCrossRefGoogle Scholar
  44. 44.
    La Vecchia C, Negri E, Franceschi S, et al.: A case-control study of diabetes mellitus and cancer risk. Br J Cancer 1994, 70:950–953.PubMedGoogle Scholar
  45. 45.
    Wideroff L, Gridley G, Mellemkjaer L, et al.: Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 1997, 89:1360–1365.PubMedCrossRefGoogle Scholar
  46. 46.
    Berkowitz D: Metabolic changes associated with obesity before and after weight reduction. JAMA 1964, 187:103–110.Google Scholar
  47. 47.
    Adler M, Schaffner F: Fatty liver hepatitis and cirrhosis in obese patients. Am J Med 1979, 67:811–816.PubMedCrossRefGoogle Scholar
  48. 48.
    Eriksson S, Eriksson KF, Bondesson L: Nonalcoholic steatohepatitis in obesity: a reversible condition. Acta Med Scand 1986, 220:83–88.PubMedCrossRefGoogle Scholar
  49. 49.
    DeFronzo RA, Barzilai N, Simonson DC: Mechanism of metformin action in obese and lean noninsulindependent diabetic subjects. J Clin Endocrinol Metab 1991, 73:1294–1301.PubMedCrossRefGoogle Scholar
  50. 50.
    Perriello G, Misericordia P, Volpi E, et al.: Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production. Diabetes 1994, 43:920–928.PubMedCrossRefGoogle Scholar
  51. 51.
    Melin B, Cherqui G, Blivet MJ, et al.: Dual effect of metformin in cultured rat hepatocytes: potentiation of insulin action and prevention of insulin-induced resistance. Metabolism 1990, 39:1089–1095.PubMedCrossRefGoogle Scholar
  52. 52.
    Lin HZ, Yang SQ, Kujhada F, et al.: Metformin reverses nonalcoholic fatty liver disease in obese leptin-deficient mice. Nat Med 2000, 6:998–1003.PubMedCrossRefGoogle Scholar
  53. 53.
    El-Mir MY, Nogueira V, Fontaine E, et al.: Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem 2000, 275:223–228.PubMedCrossRefGoogle Scholar
  54. 54.
    Kohlroser J, Mathai J, Reichheld J, et al.: Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and drug Administration. Am J Gastroenterol 2000, 95:272–276.PubMedCrossRefGoogle Scholar
  55. 55.
    Kakuma T, Lee Y, Higa M, et al.: Leptin, troglitazone, and the expression of sterol regulatory element binding proteins in liver and pancreatic islets. Proc Natl Acad Sci USA 2000, 97:8536–8541.PubMedCrossRefGoogle Scholar
  56. 56.
    Leone TC, Weinheimer CJ, Kelly DP: A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders. Proc Natl Acad Sci USA 1999, 96:7473–7478.PubMedCrossRefGoogle Scholar
  57. 57.
    Capron JP, Herve MA, Ginestron JL, et al.: Metronidazole in prevention of cholestasis associated with total parenteral nutrition. Lancet 1983, 1:446–449.PubMedCrossRefGoogle Scholar
  58. 58.
    Campfield LA, Smith FJ, Burn P: The OB protein (leptin) pathway—a link between adipose tissue mass and central neural networks. Horm Metab Res 1996, 28:619–632.PubMedCrossRefGoogle Scholar
  59. 59.
    Pelleymounter MA, Cullen MF, Baker MB, et al.: Effects of the obese gene product on body weight regulation in ob/ob mice. Science 1995, 269:540–543.PubMedCrossRefGoogle Scholar
  60. 60.
    Shimomura I, Hammer RE, Ikemoto S, et al.: Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature. 1999, 401:73–76.PubMedCrossRefGoogle Scholar
  61. 61.
    DiLuzio N, Costales F: Inhibition of ethanol and carbon tetrachloride induced fatty liver by antioxidants. Exp Mol Pathol 1965, 4:141–145.CrossRefGoogle Scholar
  62. 62.
    Lavine JE: Vitamin E treatment of non-alcoholic steatohepatitis in children: a pilot study. J Pediatr 2000, 136:734–738.PubMedCrossRefGoogle Scholar
  63. 63.
    Capron JP, Delamarre M, Dupas JL, et al.: Fasting in obesity: another cause of liver injury with alcoholic hyaline? Dig Dis Sci 1982, 54:374–377.Google Scholar
  64. 64.
    Vyberg M, Ravn V, Andersen B: Patterns of progression of liver injury following jejunoileal bypass for morbid obesity. Liver 1987, 7:271–276.PubMedGoogle Scholar

Copyright information

© Current Science Inc 2001

Authors and Affiliations

  • Ayman Koteish
    • 1
  • Anna Mae Diehl
    • 1
  1. 1.Division of GastroenterologyThe Johns Hopkins UniversityBaltimoreUSA

Personalised recommendations